Trial document





This study has been imported from ClinicalTrials.gov without additional data checks.
drksid header

  DRKS00005837

Trial Description

start of 1:1-Block title

Title

Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

EFACTS

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

This is a multi-centre, multi-national, prospective, observational study of Friedreich's
Ataxia (FRDA) with a control group to:

- obtain natural history data on individuals affected by FRDA

- relate clinical assessments and results from proteomic analyses

- expedite identification and recruitment of participants for clinical trials

- develop and validate sensitive and reliable outcome measures for detecting onset and
change over the natural course of FRDA which may also be potential outcome measures for
use in future clinical trials and clinical care

- plan for future research studies

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The EFACTS patient registry integrates prospectively and systematically collected clinical
research data (e.g. clinical tests, demographical characteristics) with access to biological
specimens (e.g. blood, urine) obtained from individuals with genetically confirmed FRDA and
unrelated control research participants.

The EFACTS patient registry is a 4-year study and eligible subjects are assessed at annual
study visits on the clinical symptoms and signs of the disease. At each study visit, general
clinical, motor function, cognitive, and Quality of Life assessments are administered. In
addition, participants are providing bio samples for the purposes of genetic testing and for
research to identify valuable biomarkers of FRDA. Biological specimens and clinical data are
made available to qualified scientists within the EFACTS network whose projects are reviewed
and approved by the EFACTS Steering Committee. Research projects should aim to advance
scientific knowledge towards establishing clinically effective treatments that delay onset
and/or slow the progression of the disease.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00005837
  •   2015/01/19
  •   2014/02/19
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT02069509  (ClinicalTrials.gov)
  •   HEALTH-F2-2010- 242193  (European Friedreich's Ataxia Consortium for Translational Studies)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Friedreich's Ataxia
  •   G11.1 -  Early-onset cerebellar ataxia
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  • [---]*
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Observational study
  •   [---]*
  •   [---]*
  •   [---]*
  •   [---]*
  •   [---]*
  •   [---]*
  •   N/A
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Disease progression as assessed by clinical examination; time frame: Participants are followed for a max. of 4 years with annual assessments

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

[---]*

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Austria
  •   Belgium
  •   France
  •   Germany
  •   Italy
  •   Spain
  •   United Kingdom
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  •  
  •  
  •  
  •  
  •  
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   [---]*
  •   2010/05/31
  •   650
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   no minimum age
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Inclusion Criteria:

- Genetic diagnosis of FRDA

- For control research participants: genetically confirmed absence of FRDA

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

[---]*

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • European Friedreich's Ataxia Consortium for Translational Studies
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • University Hospital Aachen, Dept. of Neurology
    • Jörg B. Schulz 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Jörg B. Schulz, MD 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs .
  •   1
  •   2014/02/23
* This entry means the parameter is not applicable or has not been set.